Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
SSE:600329

Watchlist Manager
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd Logo
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
SSE:600329
Watchlist
Price: 31.6 CNY -0.54% Market Closed
Market Cap: 24.3B CNY
Have any thoughts about
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd?
Write Note

Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
Accrued Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
Accrued Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accrued Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
SSE:600329
Accrued Liabilities
ÂĄ437m
CAGR 3-Years
45%
CAGR 5-Years
27%
CAGR 10-Years
21%
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Accrued Liabilities
ÂĄ2B
CAGR 3-Years
2%
CAGR 5-Years
14%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Accrued Liabilities
ÂĄ620.1m
CAGR 3-Years
74%
CAGR 5-Years
53%
CAGR 10-Years
31%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Accrued Liabilities
ÂĄ128.5m
CAGR 3-Years
456%
CAGR 5-Years
130%
CAGR 10-Years
63%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Accrued Liabilities
ÂĄ1.5B
CAGR 3-Years
74%
CAGR 5-Years
54%
CAGR 10-Years
46%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Accrued Liabilities
ÂĄ146m
CAGR 3-Years
-11%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
Glance View

Market Cap
24.3B CNY
Industry
Pharmaceuticals

Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd, rooted in the rich tapestry of traditional Chinese medicine, has carved out a substantial presence in the pharmaceutical industry. Established in a region known for its deep cultural heritage in holistic healing, the company seamlessly weaves ancient practices with modern scientific advancements. At the core of its operations, Da Ren Tang specializes in the research, development, production, and distribution of traditional Chinese medicine and pharmaceuticals. Beyond just leveraging ancient recipes, the company invests significantly in cutting-edge research to validate and enhance the efficacy of its formulations, gaining trust not only domestically but also in international markets. This blending of tradition and innovation enables Da Ren Tang to capture a diverse customer base, ranging from individuals seeking natural remedies to medical institutions incorporating holistic approaches into patient care. The economic engine of Da Ren Tang powers through a multi-faceted monetization strategy. It manufactures a broad portfolio of pharmaceutical products, including patented Chinese medicines and active pharmaceutical ingredients (APIs), which are distributed through a well-established network of pharmacies and healthcare providers. Additionally, the company has embraced the digital era by exploring e-commerce platforms, thereby expanding its reach and accessibility to tech-savvy consumers globally. By maintaining stringent quality controls and adopting sustainable practices in its production processes, Da Ren Tang not only enhances its reputation but also adheres to evolving regulatory standards worldwide. Such strategic positioning allows the company to capitalize on the growing global interest in traditional medicines, contributing significantly to its revenue streams and reinforcing its status as a prominent player in the pharmaceutical landscape.

Intrinsic Value
39.26 CNY
Undervaluation 20%
Intrinsic Value
Price

See Also

What is Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd's Accrued Liabilities?
Accrued Liabilities
437m CNY

Based on the financial report for Sep 30, 2024, Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd's Accrued Liabilities amounts to 437m CNY.

What is Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 10Y
21%

Over the last year, the Accrued Liabilities growth was 106%. The average annual Accrued Liabilities growth rates for Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd have been 45% over the past three years , 27% over the past five years , and 21% over the past ten years .

Back to Top